|Bid||0.00 x 1800|
|Ask||0.00 x 1800|
|Day's Range||56.45 - 57.54|
|52 Week Range||53.22 - 69.75|
|Beta (5Y Monthly)||0.59|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 04, 2022|
|Forward Dividend & Yield||1.96 (3.48%)|
|Ex-Dividend Date||Sep. 30, 2021|
|1y Target Est||72.84|
Our own Kwame Sarpong discusses his journey to BMS – from growing up in Ghana to his studies at Howard University.
Bristol Myers' (BMY) sBLA seeking label expansion of Reblozyl for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia gets priority review by the FDA.
Rising quarterly payouts and above-average yields make these dividend stocks worthy of your immediate attention.